Why the study?
What is the incidence and clinical presentation of life-threatening cardiac toxicity in patients treated with 5-fluorouracil?
What is the incidence and clinical presentation of life-threatening cardiac toxicity in patients treated with 5-fluorouracil?
5-fluorouracil therapy is associated with a rare (0.55%) but life-threatening risk of cardiotoxicity, likely driven by coronary vasospasm leading to ischemia, infarction, and arrhythmias.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor for ischemia during 5-FU therapy; this Level 3 observation leaves open questions on incidence and prevention.
5-Fluorouracil is widely known to be toxic to the hematopoietic and gastrointestinal systems. It also has cardiac toxicity, but this is perceived to be rare. During a 16-month period from January 1990 through April 1991, approximately 910 patients were treated with 5-fluorouracil. Five of these developed life-threatening toxicity consistent with coronary artery spasm for an incidence of .55%. The acute events occurred on the third or fourth day of the 5-day infusion and after the fourth intravenous bolus in the patient on bolus therapy. Each of the patients had ST elevation and ventricular arrhythmias, four had acute myocardial infarction, and two had cardiac arrests. In these cases and those previously reported, cardiac toxicity is consistent with drug- or metabolite-mediated increases in coronary vasomotor tone and spasm, leading to the full spectrum of signs and symptoms of myocardial ischemia in susceptible individuals.
No takes yet. Share an insight, caveat, or question.
Keefe et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: